No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.

Saved in:
Bibliographic Details
Title: No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.
Authors: Hollander EM; Department of Pharmacy, Pharmacology and Toxicology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Buma AIG; Department of Pulmonology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Leentjens J; Department of Internal Medicine, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Janssen PKC; Department of Hospital Pharmacy, VieCuri Medical Center, Venlo, the Netherlands., van den Heuvel MM; Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, the Netherlands., Burger DM; Department of Pharmacy, Pharmacology and Toxicology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Piet B; Department of Pulmonology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Ter Heine R; Department of Pharmacy, Pharmacology and Toxicology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
Source: International journal of cancer [Int J Cancer] 2026 Jun 01; Vol. 158 (11), pp. 2920-2927. Date of Electronic Publication: 2026 Jan 19.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1097-0215
DOI:10.1002/ijc.70326